Advertisement
In line with this move EUCODIS Bioscience will spin out its Frenchresearch subsidiary in a management buy-in lead by Rudy Pandjaitan, PhD,previously CEO of EUCODIS Bioscience.
Advertisement
Dr. Pandjaitan will acquire a majority stake in the new entity. Under hisleadership the new entity will develop next-generation applications of "invivo recombination". EUCODIS Bioscience will retain a strategic share in itsformer subsidiary.
"White Biotechnology, or enzyme-based products and manufacturing, is a100 billion Euro market, and EUCODIS Bioscience is well positioned to exploitthe huge commercial potential of this business", said Thomas Fischer, CEO ofEUCODIS Bioscience. "It was under Rudy's leadership that the Company hasdeveloped into this position, and we are pleased that he will continue toactively support EUCODIS Bioscience in the area of business development as aconsultant."
"EUCODIS Bioscience' technology is a powerful and proven tool for thecreation of novel enzymes", said Dr. Pandjaitan. "Even more fascinating, invivo recombination may also be used in synthetic biology, generating DNAstrands of more than 10,000 base pairs on a routine basis. It is our visionthat in vivo recombination will enable the creation of novel pathways andeven whole genomes, providing a key technology for the 'cellular factory' ofthe future."
"In vivo recombination" is EUCODIS Bioscience' proprietary,patent-protected technology for the development of industrial enzymes withnovel properties.
About EUCODIS Bioscience
EUCODIS Bioscience GmbH develops, customizes, manufactures, and marketsindustrial enzymes.
EUCODIS Bioscience' products help customers in the chemical,pharmaceutical, and food and feed industries to make manufacturing processesmore efficient and cleaner, and to generate products with superior properties.
EUCODIS Bioscience originally focused on developing enzymes forindustrial partners, including GlaxoSmithKline, Henkel, and Lohmann AnimalHealth. Since 2009, the Company also markets its own products.
Led by an experienced management team, EUCODIS Bioscience is backed byAustrian and German institutional venture capital funds, founders, andprivate investors. The Company is headquartered in Austria, Europe, with asubsidiary in Germany.For more information, please visit http://www.eucodisbioscience.com Company contact EUCODIS Bioscience: Thomas Fischer, MBA CEO EUCODIS Bioscience Campus Vienna Biocenter II Viehmarktgasse 2 a/ 2 OG A-1030 Vienna AUSTRIA +43-1-8900804 [email protected] Media contact EUCODIS Bioscience: Frank Butschbacher Investor Relations & Communications http://www.butschbacher.net +43-650-7844940 [email protected]
SOURCE EUCODIS Bioscience
